Answers are grounded in this paper and cite their sources.
Broadly protective immunity to the Lyme disease spirochete, Borreliella burgdorferi , is constrained by an overwhelming antibody response against type-specific epitopes on Outer surface protein C (OspC), a homodimeric helix-rich lipoprotein essential for early stages of spirochete dissemination in vertebrate hosts. However, the molecular basis for type-specific immunity has not been fully elucidated. In this report, we produced and characterized an OspC mouse monoclonal antibody, 8C1, that recognizes native and recombinant OspC type A (OspC A ) but not OspC types B or K, and arrests B. burgdorferi motility independent of complement. Epitope mapping by HDX-MS localized 8C1’s epitope to a protruding ridge on the apex of OspC A α-helix 3 (residues 130-150) previously known to be an immunodominant region of the molecule. Alanine scanning pinpointed 8C1’s core binding motif to a solvent exposed patch consisting of residues K 141 H 142 T 143 D 144 . In parallel, analysis of 26 Lyme disease positive serum samples confirmed antibody reactivity with this region of OspC A , with residues E 140 and D 144 as being most consequential. Our results underscore the importance of α-helix 3 as a target of type-specific epitopes on OspC A across mice and humans that should be taken into consideration in Lyme disease vaccine design.
No takes yet. Share an insight, caveat, or question.
Vance et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: